Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Prediction of Human Nonlinear Pharmacokinetics of a New Bcl-2 Inhibitor Using PBPK Modeling and Interspecies Extrapolation Strategy.

Pierrillas PB, Henin E, Ball K, Ogier J, Amiel M, Kraus-Berthier L, Chenel M, Bouzom F, Tod M.

Drug Metab Dispos. 2019 Jun;47(6):648-656. doi: 10.1124/dmd.118.085605. Epub 2019 Apr 2.

PMID:
30940629
2.

Tumor Growth Inhibition Modelling Based on Receptor Occupancy and Biomarker Activity of a New Bcl-2 Inhibitor in Mice.

Pierrillas PB, Henin E, Ogier J, Kraus-Berthier L, Chenel M, Bouzom F, Tod M.

J Pharmacol Exp Ther. 2018 Dec;367(3):414-424. doi: 10.1124/jpet.118.251694. Epub 2018 Sep 18.

PMID:
30228112
3.

Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective.

Shebley M, Sandhu P, Emami Riedmaier A, Jamei M, Narayanan R, Patel A, Peters SA, Reddy VP, Zheng M, de Zwart L, Beneton M, Bouzom F, Chen J, Chen Y, Cleary Y, Collins C, Dickinson GL, Djebli N, Einolf HJ, Gardner I, Huth F, Kazmi F, Khalil F, Lin J, Odinecs A, Patel C, Rong H, Schuck E, Sharma P, Wu SP, Xu Y, Yamazaki S, Yoshida K, Rowland M.

Clin Pharmacol Ther. 2018 Jul;104(1):88-110. doi: 10.1002/cpt.1013. Epub 2018 Feb 2. Review.

4.

Oral drug absorption in pediatrics: the intestinal wall, its developmental changes and current tools for predictions.

Nicolas JM, Bouzom F, Hugues C, Ungell AL.

Biopharm Drug Dispos. 2017 Apr;38(3):209-230. doi: 10.1002/bdd.2052. Epub 2017 Feb 6. Review.

5.

Model-based approaches for ivabradine development in paediatric population, part I: study preparation assessment.

Peigné S, Bouzom F, Brendel K, Gesson C, Fouliard S, Chenel M.

J Pharmacokinet Pharmacodyn. 2016 Feb;43(1):13-27. doi: 10.1007/s10928-015-9451-z. Epub 2015 Nov 12.

PMID:
26563503
6.

Physiologically Based Models in Regulatory Submissions: Output From the ABPI/MHRA Forum on Physiologically Based Modeling and Simulation.

Shepard T, Scott G, Cole S, Nordmark A, Bouzom F.

CPT Pharmacometrics Syst Pharmacol. 2015 Apr;4(4):221-5. doi: 10.1002/psp4.30. Epub 2015 Apr 2.

7.

Comparing translational population-PBPK modelling of brain microdialysis with bottom-up prediction of brain-to-plasma distribution in rat and human.

Ball K, Bouzom F, Scherrmann JM, Walther B, Declèves X.

Biopharm Drug Dispos. 2014 Nov;35(8):485-99. doi: 10.1002/bdd.1908. Epub 2014 Sep 17.

PMID:
25044007
8.

A physiologically based modeling strategy during preclinical CNS drug development.

Ball K, Bouzom F, Scherrmann JM, Walther B, Declèves X.

Mol Pharm. 2014 Mar 3;11(3):836-48. doi: 10.1021/mp400533q. Epub 2014 Jan 29.

PMID:
24446829
9.

S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.

Burbridge MF, Bossard CJ, Saunier C, Fejes I, Bruno A, Léonce S, Ferry G, Da Violante G, Bouzom F, Cattan V, Jacquet-Bescond A, Comoglio PM, Lockhart BP, Boutin JA, Cordi A, Ortuno JC, Pierré A, Hickman JA, Cruzalegui FH, Depil S.

Mol Cancer Ther. 2013 Sep;12(9):1749-62. doi: 10.1158/1535-7163.MCT-13-0075. Epub 2013 Jun 26.

10.

Physiologically based pharmacokinetic modelling of drug penetration across the blood-brain barrier--towards a mechanistic IVIVE-based approach.

Ball K, Bouzom F, Scherrmann JM, Walther B, Declèves X.

AAPS J. 2013 Oct;15(4):913-32. doi: 10.1208/s12248-013-9496-0. Epub 2013 Jun 20. Review.

12.

Quantitative mass spectrometry imaging of propranolol and olanzapine using tissue extinction calculation as normalization factor.

Hamm G, Bonnel D, Legouffe R, Pamelard F, Delbos JM, Bouzom F, Stauber J.

J Proteomics. 2012 Aug 30;75(16):4952-4961. doi: 10.1016/j.jprot.2012.07.035. Epub 2012 Jul 26.

PMID:
22842155
13.

Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs?

Bouzom F, Ball K, Perdaems N, Walther B.

Biopharm Drug Dispos. 2012 Mar;33(2):55-71. doi: 10.1002/bdd.1767. Epub 2012 Jan 26. Review.

PMID:
22228149
14.

Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass.

Bruyère A, Declèves X, Bouzom F, Ball K, Marques C, Treton X, Pocard M, Valleur P, Bouhnik Y, Panis Y, Scherrmann JM, Mouly S.

Mol Pharm. 2010 Oct 4;7(5):1596-607. doi: 10.1021/mp100015x. Epub 2010 Aug 4.

PMID:
20604570
15.

Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil.

Perdaems N, Blasco H, Vinson C, Chenel M, Whalley S, Cazade F, Bouzom F.

Clin Pharmacokinet. 2010 Apr;49(4):239-58. doi: 10.2165/11318130-000000000-00000.

PMID:
20214408
16.

Development of an optimized procedure for the preparation of rat intestinal microsomes: comparison of hepatic and intestinal microsomal cytochrome P450 enzyme activities in two rat strains.

Bruyère A, Declevès X, Bouzom F, Proust L, Martinet M, Walther B, Parmentier Y.

Xenobiotica. 2009 Jan;39(1):22-32. doi: 10.1080/00498250802517714 .

PMID:
19219745
17.

Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 1: comparison of uniresponse and multiresponse designs using PopDes.

Chenel M, Bouzom F, Aarons L, Ogungbenro K.

J Pharmacokinet Pharmacodyn. 2008 Dec;35(6):635-59. doi: 10.1007/s10928-008-9104-6. Epub 2009 Jan 7.

PMID:
19130188
18.

Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 2: clinical trial results.

Chenel M, Bouzom F, Cazade F, Ogungbenro K, Aarons L, Mentré F.

J Pharmacokinet Pharmacodyn. 2008 Dec;35(6):661-81. doi: 10.1007/s10928-008-9105-5. Epub 2009 Jan 7.

19.

Pharmacokinetic predictions in children by using the physiologically based pharmacokinetic modelling.

Bouzom F, Walther B.

Fundam Clin Pharmacol. 2008 Dec;22(6):579-87. doi: 10.1111/j.1472-8206.2008.00648.x. Review.

PMID:
19049658
20.
21.

S 12340: a potent inhibitor of the oxidative modification of low-density lipoprotein in vitro and ex vivo in WHHL rabbits.

Breugnot C, Privat S, Guillonneau C, Regnier G, Bouzom F, Vilaine JP, Lenaers A.

J Pharmacol Exp Ther. 1994 May;269(2):515-20.

PMID:
8182520

Supplemental Content

Loading ...
Support Center